Avandia And Actos Add “Black Boxes” For Heart Failure
Executive Summary
As an interim step in its ongoing review of thiazolidinedione cardiac safety, FDA has called for revised class labeling for the TZDs featuring strengthened warnings about the incidence of heart failure and contraindications for patients with existing heart failure
You may also be interested in...
Avandia Retaining Preferred Status On 2008 Part D Formularies – For Now
So far GlaxoSmithKline's Avandia (rosiglitazone) appears to be retaining its tier 2 status on the 2008 formularies of major Medicare Part D plans despite safety concerns that surfaced earlier this year
Avandia Retaining Preferred Status On 2008 Part D Formularies – For Now
So far GlaxoSmithKline's Avandia (rosiglitazone) appears to be retaining its tier 2 status on the 2008 formularies of major Medicare Part D plans despite safety concerns that surfaced earlier this year
Avandia Safety Review Planned By U. Miami-Humana Data Mining Venture
A safety analysis of GlaxoSmithKline's Avandia is among the first evaluations planned by a pharmacovigilance initiative announced by the University of Miami and Humana Aug. 22